Kiniksa is a biopharmaceutical company that develops and commercializes therapies for cardiovascular and autoimmune diseases with significant unmet medical need. The company's commercial product is ARCALYST, an IL-1 inhibitor approved for recurrent pericarditis and other inflammatory conditions, which it co-promotes in the United States under a profit-split agreement with Regeneron and has out-licensed to regional partners; ARCALYST is administered as a weekly subcutaneous injection to patients treated by cardiologists and rheumatologists through specialty pharmacy channels. Kiniksa generates revenue through a profit-split model on domestic ARCALYST sales, royalties and milestone payments from out-licensing agreements (including $80 million in upfront payments and up to $570 million in contingent payments from prior deals), and the advancement of pipeline candidates such as KPL-387, an independently developed monoclonal antibody designed for monthly dosing to expand the recurrent pericarditis market.